Buprenorphine And Naloxone Tablet
Product Images NDC 87441-001

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Buprenorphine And Naloxone (NDC 87441-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Uds Buprenorphine Label)

Label (Uds Buprenorphine Label)
Label for Buprenorphine and Naloxone Sublingual Tablets USP, 8 mg / 2 mg strength. The label includes NDC 87441-001-01, controlled substance class CIII marking, and indicates the tablets are Rx only. It provides a pharmacist instruction to dispense the medication guide and storage instructions at 20° to 25°C (68° to 77°F). The label lists the active ingredients buprenorphine hydrochloride and naloxone hydrochloride, repackager Unit Dose Solutions, Inc., and distributor Tuckahoe Enterprises, LLC.*
FDA Label Image

Chemical Structure (Buprenorphine 01)

Chemical Structure (Buprenorphine 01)
Chemical structure diagram of Buprenorphine, showing molecular bonds and functional groups, including hydroxyl, methoxy, and cyclopropyl groups, labeled with HCl indicating the hydrochloride salt form.*
FDA Label Image

Chemical Structure (Buprenorphine 02)

Chemical Structure (Buprenorphine 02)
Chemical structure diagram of Buprenorphine hydrochloride dihydrate, showing the molecular structure with hydroxyl, ketone, and nitrogen functional groups, labeled with HCl · 2H2O.*
FDA Label Image

Image (Buprenorphine 03)

Image (Buprenorphine 03)
An instructional illustration showing a person lifting their upper lip and placing a sublingual tablet on the inner surface of the lower front teeth or gum area. The diagram is meant to demonstrate the proper placement of a sublingual tablet for buprenorphine and naloxone administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.